MAY 05, 2022
Comprehensive Ophthalmology, Ocular Pathology/Oncology, Retina/Vitreous
0.5 General AMA PRA Category 1 Credits™
Drs. Maura Di Nicola and Basil Williams run through the diagnosis and management of radiation retinopathy, including the applications of anti-VEGF agents and ongoing clinical trials.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
Release: May 5, 2022; expires May 5, 2025
Planner/Faculty: Dr. Sridhar reports no relevant financial disclosures.
Faculty: Dr. Basil Williams receives consulting fees from Castle Biosciences, Genentech, and Allergan. Dr. Di Nicola reports no financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for the diagnosis and management of radiation retinopathy, and outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.